Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems

Authors: Gustavo A Viani, Marcus S Castilho, João V Salvajoli, Antonio Cassio A Pellizzon, Paulo E Novaes, Flavio S Guimarães, Maria A Conte, Ricardo C Fogaroli

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Brain metastases (BM) are the most common form of intracranial cancer. The incidence of BM seems to have increased over the past decade. Recursive partitioning analysis (RPA) of data from three Radiation Therapy Oncology Group (RTOG) trials (1200 patients) has allowed three prognostic groups to be identified. More recently a simplified stratification system that uses the evaluation of three main prognostics factors for radiosurgery in BM was developed.

Methods

To analyze the overall survival rate (OS), prognostic factors affecting outcomes and to estimate the potential improvement in OS for patients with BM from breast cancer, stratified by RPA class and brain metastases score (BS-BM). From January 1996 to December 2004, 174 medical records of patients with diagnosis of BM from breast cancer, who received WBRT were analyzed. The surgery followed by WBRT was used in 15.5% of patients and 84.5% of others patients were submitted at WBRT alone; 108 patients (62.1%) received the fractionation schedule of 30 Gy in 10 fractions. Solitary BM was present in 37.9 % of patients. The prognostic factors evaluated for OS were: age, Karnofsky Performance Status (KPS), number of lesions, localization of lesions, neurosurgery, chemotherapy, absence extracranial disease, RPA class, BS-BM and radiation doses and fractionation.

Results

The OS in 1, 2 and 3 years was 33.4 %, 16.7%, and 8.8 %, respectively. The RPA class analysis showed strong relation with OS (p < 0.0001). The median survival time by RPA class in months was: class I 11.7, class II 6.2 and class III 3.0. The significant prognostic factors associated with better OS were: higher KPS (p < 0.0001), neurosurgery (P < 0.0001), single metastases (p = 0.003), BS-BM (p < 0.0001), control primary tumor (p = 0.002) and absence of extracranial metastases (p = 0.001). In multivariate analysis, the factors associated positively with OS were: neurosurgery (p < 0.0001), absence of extracranial metastases (p <0.0001) and RPA class I (p < 0.0001).

Conclusion

Our data suggests that patients with BM from breast cancer classified as RPA class I may be effectively treated with local resection followed by WBRT, mainly in those patients with single BM, higher KPS and cranial extra disease controlled. RPA class was shown to be the most reliable indicators of survival.
Appendix
Available only for authorised users
Literature
1.
go back to reference Delattre JY, Krol G, Thaler HT, Posner JB: Distribution of brain metastases. Arch Neurol. 1988, 45: 741-44.CrossRefPubMed Delattre JY, Krol G, Thaler HT, Posner JB: Distribution of brain metastases. Arch Neurol. 1988, 45: 741-44.CrossRefPubMed
2.
go back to reference Coia LR: The role of radiotherapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys. 1992, 23: 229-238.CrossRefPubMed Coia LR: The role of radiotherapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys. 1992, 23: 229-238.CrossRefPubMed
3.
go back to reference DiStefano A, Yong Yap H, Hortobagyi GN, Blumenschein GR: The natural history of breast cancer patients with brain metastases. Cancer. 1979, 44: 1913-1918. 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D.CrossRefPubMed DiStefano A, Yong Yap H, Hortobagyi GN, Blumenschein GR: The natural history of breast cancer patients with brain metastases. Cancer. 1979, 44: 1913-1918. 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D.CrossRefPubMed
4.
go back to reference Gutin PH: Corticosteroid therapy in patients with cerebral tumor: Benefits, mechanisms, problems, practicalities. Semin Oncol. 1975, 2: 49-56.PubMed Gutin PH: Corticosteroid therapy in patients with cerebral tumor: Benefits, mechanisms, problems, practicalities. Semin Oncol. 1975, 2: 49-56.PubMed
5.
go back to reference Pladdet I, Boven E, Nauta J, Pinedo HM: Palliative care for brain metastases of solid tumour types. Neth JMed. 1989, 34: 10-21. Pladdet I, Boven E, Nauta J, Pinedo HM: Palliative care for brain metastases of solid tumour types. Neth JMed. 1989, 34: 10-21.
6.
go back to reference Cairncross JG, Kim J-H, Posner JB: Radiation therapy for brain metastases. Ann Neurol. 1980, 7: 529-541. 10.1002/ana.410070606.CrossRefPubMed Cairncross JG, Kim J-H, Posner JB: Radiation therapy for brain metastases. Ann Neurol. 1980, 7: 529-541. 10.1002/ana.410070606.CrossRefPubMed
7.
go back to reference Bendell JC, Domchek SM, Burstein HJ: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003, 97: 2972-77. 10.1002/cncr.11436.CrossRefPubMed Bendell JC, Domchek SM, Burstein HJ: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003, 97: 2972-77. 10.1002/cncr.11436.CrossRefPubMed
8.
go back to reference Crivellari D, Pagani O, Veronesi A: High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001, 12: 353-56. 10.1023/A:1011132609055.CrossRefPubMed Crivellari D, Pagani O, Veronesi A: High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001, 12: 353-56. 10.1023/A:1011132609055.CrossRefPubMed
9.
go back to reference Gaspar L, Scott C, Rotman M: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997, 37: 745-751. 10.1016/S0360-3016(96)00619-0.CrossRefPubMed Gaspar L, Scott C, Rotman M: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997, 37: 745-751. 10.1016/S0360-3016(96)00619-0.CrossRefPubMed
10.
go back to reference Sneed PK, Suh JH, Goetsch SJ: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002, 53: 519-526. 10.1016/S0360-3016(02)02770-0.CrossRefPubMed Sneed PK, Suh JH, Goetsch SJ: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002, 53: 519-526. 10.1016/S0360-3016(02)02770-0.CrossRefPubMed
11.
go back to reference Sanghavi SN, Miranpuri SS, Chappell R: Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001, 51: 426-434. 10.1016/S0360-3016(01)01622-4.CrossRefPubMed Sanghavi SN, Miranpuri SS, Chappell R: Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001, 51: 426-434. 10.1016/S0360-3016(01)01622-4.CrossRefPubMed
12.
go back to reference Chidel MA, Suh JH, Reddy CA: Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol. 2000, 47: 993-999. 10.1016/S0360-3016(00)00527-7.CrossRef Chidel MA, Suh JH, Reddy CA: Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol. 2000, 47: 993-999. 10.1016/S0360-3016(00)00527-7.CrossRef
13.
go back to reference Lorenzoni J, Devriendt D, Massager N: Estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004, 60: 218-224. 10.1016/j.ijrobp.2004.02.017.CrossRefPubMed Lorenzoni J, Devriendt D, Massager N: Estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004, 60: 218-224. 10.1016/j.ijrobp.2004.02.017.CrossRefPubMed
14.
go back to reference Saito EY, Viani GA, Ferrigno R, Nakamura RA, Novaes PE, Pellizzon CA, Fogaroli RC, Conte MA, Salvajoli JV: Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol. 2006, 29 (1): 20-10.1186/1748-717X-1-20.CrossRef Saito EY, Viani GA, Ferrigno R, Nakamura RA, Novaes PE, Pellizzon CA, Fogaroli RC, Conte MA, Salvajoli JV: Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat Oncol. 2006, 29 (1): 20-10.1186/1748-717X-1-20.CrossRef
15.
go back to reference Patchell RA, Tibbs PA, Walsh JW: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990, 322: 494-500.CrossRefPubMed Patchell RA, Tibbs PA, Walsh JW: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990, 322: 494-500.CrossRefPubMed
16.
go back to reference Vecht CJ, Haaxma-Reiche H, Noordijk EM: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol. 1993, 33: 583-90. 10.1002/ana.410330605.CrossRefPubMed Vecht CJ, Haaxma-Reiche H, Noordijk EM: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol. 1993, 33: 583-90. 10.1002/ana.410330605.CrossRefPubMed
17.
go back to reference Tsukada Y, Fouad A, Pickren JW, Lane WW: Central nervous system metastasis from breast carcinoma, autopsy study. Cancer. 1983, 52: 2349-2354. 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B.CrossRefPubMed Tsukada Y, Fouad A, Pickren JW, Lane WW: Central nervous system metastasis from breast carcinoma, autopsy study. Cancer. 1983, 52: 2349-2354. 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B.CrossRefPubMed
18.
go back to reference Petrovich Z, Yu C, Giannotta SL, O'Day S, Apuzzo MLJ: Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg. 2002, 97 (Suppl 5): 499-506.PubMed Petrovich Z, Yu C, Giannotta SL, O'Day S, Apuzzo MLJ: Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg. 2002, 97 (Suppl 5): 499-506.PubMed
19.
go back to reference Mizutani Y, Yamashita T, Sakamoto G: Radiation therapy for brain metastases from breast cancer by histological classification. Nippon Acta Radiol. 2001, 61: 89-95.PubMed Mizutani Y, Yamashita T, Sakamoto G: Radiation therapy for brain metastases from breast cancer by histological classification. Nippon Acta Radiol. 2001, 61: 89-95.PubMed
20.
go back to reference Fokstuen T, Wilking N, Rutqvist LE: Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000, 62: 211-216. 10.1023/A:1006486423827.CrossRefPubMed Fokstuen T, Wilking N, Rutqvist LE: Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000, 62: 211-216. 10.1023/A:1006486423827.CrossRefPubMed
21.
go back to reference Firlik KS, Kondziolka D, Flickinger JC: Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol. 2000, 7: 333-338. 10.1007/s10434-000-0333-1.CrossRefPubMed Firlik KS, Kondziolka D, Flickinger JC: Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol. 2000, 7: 333-338. 10.1007/s10434-000-0333-1.CrossRefPubMed
22.
go back to reference Pieper DR, Hess KR, Sawaya RE: Role of surgery in the treatment of brain metastases in patients with breast cancer. Ann Surg Oncol. 1997, 4: 481-490. 10.1007/BF02303672.CrossRefPubMed Pieper DR, Hess KR, Sawaya RE: Role of surgery in the treatment of brain metastases in patients with breast cancer. Ann Surg Oncol. 1997, 4: 481-490. 10.1007/BF02303672.CrossRefPubMed
23.
go back to reference Wronski M, Arbit E, McCormick B: Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer. 1997, 80: 1746-1754. 10.1002/(SICI)1097-0142(19971101)80:9<1746::AID-CNCR8>3.0.CO;2-C.CrossRefPubMed Wronski M, Arbit E, McCormick B: Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer. 1997, 80: 1746-1754. 10.1002/(SICI)1097-0142(19971101)80:9<1746::AID-CNCR8>3.0.CO;2-C.CrossRefPubMed
24.
go back to reference Lentzsch S, Reichardt P, Weber F: Brain metastases in breast cancer: Prognostic factors and management. Euro J Cancer. 1999, 35: 580-585. 10.1016/S0959-8049(98)00421-3.CrossRef Lentzsch S, Reichardt P, Weber F: Brain metastases in breast cancer: Prognostic factors and management. Euro J Cancer. 1999, 35: 580-585. 10.1016/S0959-8049(98)00421-3.CrossRef
25.
go back to reference Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys. 2002, 54: 810-817. 10.1016/S0360-3016(02)02967-X.CrossRefPubMed Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys. 2002, 54: 810-817. 10.1016/S0360-3016(02)02967-X.CrossRefPubMed
26.
go back to reference Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980, 6: 1-9.CrossRefPubMed Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980, 6: 1-9.CrossRefPubMed
27.
go back to reference Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R: A randomized phase III protocol for the evaluation of misonidazole combined nwith radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991, 20: 53-58.CrossRefPubMed Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R: A randomized phase III protocol for the evaluation of misonidazole combined nwith radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991, 20: 53-58.CrossRefPubMed
28.
go back to reference Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997, 39: 571-574. 10.1016/S0360-3016(97)00341-6.CrossRefPubMed Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997, 39: 571-574. 10.1016/S0360-3016(97)00341-6.CrossRefPubMed
29.
go back to reference Sause WT, Scott C, Krisch R, Rotman M, Sneed PK, Janjan N, Davis L, Curran W, Choi KN, Selim H: Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys. 1993, 26: 653-657.CrossRefPubMed Sause WT, Scott C, Krisch R, Rotman M, Sneed PK, Janjan N, Davis L, Curran W, Choi KN, Selim H: Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys. 1993, 26: 653-657.CrossRefPubMed
30.
go back to reference Noordijk EM, Vecht CJ, Haaxma-Reiche H: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994, 29: 711-717.CrossRefPubMed Noordijk EM, Vecht CJ, Haaxma-Reiche H: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994, 29: 711-717.CrossRefPubMed
31.
go back to reference Mintz AH, Kestle J, Rathbone MP: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996, 78: 1470-1476. 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X.CrossRefPubMed Mintz AH, Kestle J, Rathbone MP: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996, 78: 1470-1476. 10.1002/(SICI)1097-0142(19961001)78:7<1470::AID-CNCR14>3.0.CO;2-X.CrossRefPubMed
32.
go back to reference Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E: Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006, 24 (1): 13-5. 10.1200/JCO.2004.00.1768.CrossRef Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E: Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol. 2006, 24 (1): 13-5. 10.1200/JCO.2004.00.1768.CrossRef
Metadata
Title
Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems
Authors
Gustavo A Viani
Marcus S Castilho
João V Salvajoli
Antonio Cassio A Pellizzon
Paulo E Novaes
Flavio S Guimarães
Maria A Conte
Ricardo C Fogaroli
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-53

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine